Artificial intelligence startup Anthropic and medical knowledge platform OpenEvidence said on Tuesday they are collaborating to bring AI-powered clinical decision support to physicians in regions that have limited access to the technology, according to a Reuters report. Under the partnership, the AI tool that doctors use to query medical research and treatment guidelines will be rolled out free of charge to physicians in roughly 100 countries.
The move marks one of the most aggressive international expansion efforts yet in medical AI, and it lands at a moment when the use of large language models in clinical settings is shifting from novelty to daily habit. For readers following the latest AI developments, it is also the clearest sign yet that Anthropic intends to compete for the healthcare market, not just the coding and enterprise segments where its Claude models built their reputation.
What the Partnership Actually Does
OpenEvidence provides answers to doctors' questions by drawing on medical knowledge resources, allowing clinicians to search studies, guidelines and treatment evidence in a conversational interface. The platform is already deeply embedded in American medicine: according to Reuters, its search engine is consulted daily, on average, by more than 40% of US doctors, across more than 10,000 hospitals and medical centers nationwide.
The new agreement pairs that distribution with Anthropic's AI models. By making the combined offering free in about 100 countries, the companies are targeting physicians in health systems that lack the budgets, infrastructure or regulatory clearance to adopt American medical software. The announcement was reported by Reuters health correspondent Nancy Lapid, who noted the collaboration is aimed at expanding access to AI-powered clinical decision support for physicians in regions that do not currently have it.
Neither company has publicly detailed the financial terms of the arrangement, and it remains unclear how the free tier will be sustained long-term or which countries will receive access first.
Why Anthropic Is Pushing Into Healthcare
The partnership was announced the same day Anthropic launched Claude Opus 5.5, its newest frontier model, and the timing is unlikely to be accidental. Healthcare is one of the few industries where AI vendors can charge for accuracy rather than novelty, and where a verified knowledge base matters as much as raw model capability.
Anthropic has been signaling its healthcare ambitions for most of the year. In January, the company published a formal commitment to advancing Claude in healthcare and the life sciences, and since then it has pursued certifications and integrations aimed at clinical use. The OpenEvidence deal gives those efforts something previous announcements lacked: instant reach into the daily workflows of tens of thousands of practicing physicians.
For OpenEvidence, founded by entrepreneur Daniel Nadler, the deal addresses the main criticism of its otherwise rapid ascent. The company was named to CNBC's list of most promising startups and Time's 100 Most Influential People in AI in 2026, but its footprint has been overwhelmingly American. A free international tier could make it the default research tool for doctors in markets where competitors have barely set foot.
A Crowded and Scrutinized Field
Medical AI remains a contested space. A Fortune report in July described a new medical AI study that found the same flaw in OpenEvidence, OpenAI, Anthropic and Doximity products, underscoring that even widely adopted clinical tools face open questions about reliability and citation accuracy. NBC News reported in May that most US doctors are quietly using AI tools like OpenEvidence, often without their patients knowing it.
That scrutiny will only intensify as the tools cross borders. A tool used in a well-resourced Boston hospital operates within a dense web of liability rules and institutional oversight; the same tool offered free to a clinic in a country with no AI-specific medical regulations raises harder questions about who is responsible when an AI-generated answer contributes to a bad outcome. The companies have not said what safeguards, disclaimers or clinician-training requirements will accompany the 100-country rollout.
What It Means for Global Health Access
The strongest argument for the partnership is the one the companies themselves make: most of the world's physicians practice in health systems with limited access to up-to-date research, and clinical decision support has historically been expensive enterprise software. If a free, AI-assisted research layer reaches doctors who today rely on outdated textbooks, the public health impact could be substantial — and it would give Anthropic a distribution story its rivals cannot easily match.
The risks are equally real. Machine-translated interfaces, uneven internet access and differences in treatment guidelines between countries could all blunt the tool's usefulness, and regulators in Europe and elsewhere have shown little patience for AI products that arrive before their oversight frameworks do.
For now, the announcement is a statement of intent: medical AI's next growth market is not the United States, and the companies that move first will define how the rest of the world uses it.
---
Stay Ahead of AIGet the latest AI news, analysis, and breakthroughs — all in one place.
Read more AI news →
